$NVRO
NEVRO CORP

2019 Q3 Form 10-Q Financial Statement

#000156459019041110 Filed on November 06, 2019

View on sec.gov

Income Statement

Concept 2019 Q3 2018 Q3 2018 Q2
Revenue $100.2M $95.63M $96.08M
YoY Change 4.74% 16.26% 23.15%
Cost Of Revenue $30.22M $28.38M $28.16M
YoY Change 6.48% 16.8% 16.63%
Gross Profit $69.94M $67.25M $67.92M
YoY Change 4.0% 16.06% 26.08%
Gross Profit Margin 69.83% 70.32% 70.69%
Selling, General & Admin $72.91M $64.01M $64.70M
YoY Change 13.9% 20.77% 19.21%
% of Gross Profit 104.24% 95.18% 95.26%
Research & Development $13.02M $12.48M $11.40M
YoY Change 4.34% 32.74% 19.53%
% of Gross Profit 18.61% 18.56% 16.78%
Depreciation & Amortization $1.112M $1.078M $952.0K
YoY Change 3.15% 63.33% 52.81%
% of Gross Profit 1.59% 1.6% 1.4%
Operating Expenses $85.92M $76.49M $76.12M
YoY Change 12.34% 22.57% 19.29%
Operating Profit -$15.98M -$9.237M -$8.201M
YoY Change 73.04% 109.08% -17.48%
Interest Expense $2.755M -$1.300M $2.579M
YoY Change -311.92% -23.53% 5.09%
% of Operating Profit
Other Income/Expense, Net -$291.0K -$100.0K -$592.0K
YoY Change 191.0% -133.33% -242.31%
Pretax Income -$17.43M -$10.70M -$10.24M
YoY Change 62.87% 81.36% -8.83%
Income Tax $420.0K $600.0K $383.0K
% Of Pretax Income
Net Earnings -$17.85M -$11.27M -$10.62M
YoY Change 58.43% 80.82% -8.53%
Net Earnings / Revenue -17.82% -11.78% -11.05%
Basic Earnings Per Share
Diluted Earnings Per Share -$576.1K -$375.4K -$353.3K
COMMON SHARES
Basic Shares Outstanding 30.03M
Diluted Shares Outstanding

Balance Sheet

Concept 2019 Q3 2018 Q3 2018 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments $232.8M $258.0M $263.9M
YoY Change -9.78% -4.94% 0.23%
Cash & Equivalents $49.34M $21.98M $41.64M
Short-Term Investments $183.4M $236.6M $223.0M
Other Short-Term Assets $6.500M $7.200M $6.800M
YoY Change -9.72% 14.29% 6.25%
Inventory $90.73M $93.60M $95.00M
Prepaid Expenses
Receivables $70.81M $74.00M $66.00M
Other Receivables $0.00 $0.00 $0.00
Total Short-Term Assets $400.8M $432.8M $431.6M
YoY Change -7.39% 1.45% 5.19%
LONG-TERM ASSETS
Property, Plant & Equipment $11.72M $13.30M $13.60M
YoY Change -11.87% 84.72% 88.89%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $11.91M $4.900M $4.600M
YoY Change 143.1% 16.67% 39.39%
Total Long-Term Assets $46.94M $18.30M $18.30M
YoY Change 156.49% 61.95% 74.29%
TOTAL ASSETS
Total Short-Term Assets $400.8M $432.8M $431.6M
Total Long-Term Assets $46.94M $18.30M $18.30M
Total Assets $447.7M $451.1M $449.9M
YoY Change -0.75% 3.01% 6.92%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $19.77M $20.20M $23.50M
YoY Change -2.13% 13.48% 113.64%
Accrued Expenses $45.05M $31.30M $27.90M
YoY Change 43.92% 10.99% 16.25%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $68.33M $53.80M $53.50M
YoY Change 27.0% 10.7% 44.38%
LONG-TERM LIABILITIES
Long-Term Debt $158.3M $150.5M $148.6M
YoY Change 5.16% 5.03% 5.0%
Other Long-Term Liabilities $1.712M $2.400M $2.100M
YoY Change -28.67% 33.33% 49.15%
Total Long-Term Liabilities $160.0M $150.5M $150.7M
YoY Change 6.3% 3.73% 5.44%
TOTAL LIABILITIES
Total Short-Term Liabilities $68.33M $53.80M $53.50M
Total Long-Term Liabilities $160.0M $150.5M $150.7M
Total Liabilities $249.6M $206.7M $204.3M
YoY Change 20.77% 6.71% 13.51%
SHAREHOLDERS EQUITY
Retained Earnings -$396.0M
YoY Change
Common Stock $594.7M
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $198.1M $244.3M $245.6M
YoY Change
Total Liabilities & Shareholders Equity $447.7M $451.1M $449.9M
YoY Change -0.75% 3.01% 6.92%

Cashflow Statement

Concept 2019 Q3 2018 Q3 2018 Q2
OPERATING ACTIVITIES
Net Income -$17.85M -$11.27M -$10.62M
YoY Change 58.43% 80.82% -8.53%
Depreciation, Depletion And Amortization $1.112M $1.078M $952.0K
YoY Change 3.15% 63.33% 52.81%
Cash From Operating Activities -$3.370M -$5.600M $1.130M
YoY Change -39.82% -203.32% -132.47%
INVESTING ACTIVITIES
Capital Expenditures -$660.0K -$1.420M -$1.440M
YoY Change -53.52% 97.22% 37.14%
Acquisitions
YoY Change
Other Investing Activities -$11.87M -$13.00M $9.410M
YoY Change -8.69% -216.18% 41.93%
Cash From Investing Activities -$12.54M -$14.43M $7.980M
YoY Change -13.1% -237.82% 42.75%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 3.000M 420.0K 4.310M
YoY Change 614.29% -86.41% 26.39%
NET CHANGE
Cash From Operating Activities -3.370M -5.600M 1.130M
Cash From Investing Activities -12.54M -14.43M 7.980M
Cash From Financing Activities 3.000M 420.0K 4.310M
Net Change In Cash -12.91M -19.61M 13.42M
YoY Change -34.17% -203.32% 143.12%
FREE CASH FLOW
Cash From Operating Activities -$3.370M -$5.600M $1.130M
Capital Expenditures -$660.0K -$1.420M -$1.440M
Free Cash Flow -$2.710M -$4.180M $2.570M
YoY Change -35.17% -168.08% -205.76%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2018Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
12801000
CY2018Q4 us-gaap Assets Current
AssetsCurrent
443859000
CY2019Q1 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
521000
CY2019Q1 us-gaap Stockholders Equity
StockholdersEquity
214099000
CY2019Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
2233000
CY2019Q3 nvro Litigation Amendment Period
LitigationAmendmentPeriod
P21D
nvro Employee Stock Purchase Plan Offering Period
EmployeeStockPurchasePlanOfferingPeriod
P6M
nvro Employee Stock Purchase Plan Offering Period
EmployeeStockPurchasePlanOfferingPeriod
P6M
CY2019Q2 us-gaap Adjustments Related To Tax Withholding For Share Based Compensation
AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation
406000
CY2019Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-17647000
CY2019Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.58
CY2018Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
290000000
CY2018Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
30263536
CY2018Q4 us-gaap Stockholders Equity
StockholdersEquity
245483000
CY2019Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
447738000
CY2019Q3 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
30929938
CY2019Q2 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
4095000
CY2019Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
9724000
CY2019Q2 us-gaap Net Income Loss
NetIncomeLoss
-28021000
CY2018Q4 us-gaap Stockholders Equity
StockholdersEquity
245483000
CY2019Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
1928000
CY2019Q1 us-gaap Adjustments Related To Tax Withholding For Share Based Compensation
AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation
154000
CY2019Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
10397000
CY2019Q1 us-gaap Net Income Loss
NetIncomeLoss
-44076000
CY2019Q2 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
-182000
CY2019Q2 us-gaap Stockholders Equity
StockholdersEquity
201542000
CY2019Q3 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
3505000
CY2019Q3 us-gaap Adjustments Related To Tax Withholding For Share Based Compensation
AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation
497000
CY2019Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
11194000
CY2019Q3 us-gaap Net Income Loss
NetIncomeLoss
-17847000
CY2019Q3 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
200000
CY2018Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
23505000
CY2019Q3 us-gaap Assets Current
AssetsCurrent
400801000
CY2019Q3 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
183429000
dei Security12b Title
Security12bTitle
Common Stock, $0.001 par value per share
dei Entity Address Address Line1
EntityAddressAddressLine1
1800 Bridge Parkway
dei Entity Address City Or Town
EntityAddressCityOrTown
Redwood City
CY2018Q4 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
213281000
CY2019Q3 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
70807000
CY2018Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
80656000
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Entity Small Business
EntitySmallBusiness
false
dei Entity Address State Or Province
EntityAddressStateOrProvince
CA
CY2019Q3 us-gaap Inventory Net
InventoryNet
90730000
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
dei Entity Shell Company
EntityShellCompany
false
dei Entity File Number
EntityFileNumber
001-36715
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
56-2568057
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
94065
dei City Area Code
CityAreaCode
650
dei Local Phone Number
LocalPhoneNumber
251-0005
CY2018Q4 us-gaap Inventory Net
InventoryNet
92035000
CY2018Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
6621000
dei Document Transition Report
DocumentTransitionReport
false
CY2019Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
11721000
CY2018Q3 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
28382000
CY2019Q3 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
30222000
CY2018Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
5850000
CY2018Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
119000
CY2019Q3 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
22348000
CY2018Q4 us-gaap Liabilities Current
LiabilitiesCurrent
62414000
CY2018Q4 us-gaap Restricted Cash And Cash Equivalents Noncurrent
RestrictedCashAndCashEquivalentsNoncurrent
606000
CY2018Q4 us-gaap Assets
Assets
463116000
CY2018Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
38790000
CY2018Q4 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
152394000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
275881000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
279345000
CY2019Q3 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
6497000
CY2018Q3 us-gaap Net Income Loss
NetIncomeLoss
-11265000
CY2018Q3 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
114000
CY2018Q3 us-gaap Stockholders Equity
StockholdersEquity
244302000
CY2019Q3 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
200000
CY2019Q3 us-gaap Gross Profit
GrossProfit
69940000
us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
88789000
CY2018Q3 us-gaap Gross Profit
GrossProfit
67248000
CY2018Q3 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
64007000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
42084000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
34979000
us-gaap Gross Profit
GrossProfit
197170000
us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
82175000
us-gaap Gross Profit
GrossProfit
187092000
CY2019Q3 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
72905000
CY2018Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
12478000
us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
229806000
CY2019Q3 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P5Y6M21D
CY2019Q3 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.070
CY2019Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
45048000
CY2019Q3 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
3509000
CY2019Q3 us-gaap Liabilities Current
LiabilitiesCurrent
68327000
CY2019Q3 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
158278000
CY2019Q3 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
21324000
CY2019Q3 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
1712000
CY2018Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
2825000
CY2019Q3 us-gaap Liabilities
Liabilities
249641000
us-gaap Operating Lease Cost
OperatingLeaseCost
3807000
CY2019Q3 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2018Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2019Q3 us-gaap Preferred Stock Value
PreferredStockValue
CY2018Q4 us-gaap Preferred Stock Value
PreferredStockValue
dei Security Exchange Name
SecurityExchangeName
NYSE
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2019Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
49338000
CY2018Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
51266000
CY2019Q3 us-gaap Allowance For Doubtful Accounts Receivable Current
AllowanceForDoubtfulAccountsReceivableCurrent
925000
CY2018Q4 us-gaap Allowance For Doubtful Accounts Receivable Current
AllowanceForDoubtfulAccountsReceivableCurrent
824000
CY2019Q3 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
11912000
CY2019Q3 us-gaap Restricted Cash And Cash Equivalents Noncurrent
RestrictedCashAndCashEquivalentsNoncurrent
956000
CY2019Q3 us-gaap Assets
Assets
447738000
CY2019Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
19770000
CY2018Q4 us-gaap Liabilities
Liabilities
217633000
CY2019Q3 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2018Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2019Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2018Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2018Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2019Q3 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2018Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2019Q3 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2019Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2018Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2019Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
290000000
CY2019Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
30994005
CY2019Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
30994005
CY2018Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
30263536
CY2019Q3 us-gaap Common Stock Value
CommonStockValue
31000
CY2018Q4 us-gaap Common Stock Value
CommonStockValue
30000
CY2019Q3 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
594630000
CY2018Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
552612000
CY2019Q3 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-538000
CY2018Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-1077000
CY2019Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-396026000
CY2018Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-306082000
CY2019Q3 us-gaap Stockholders Equity
StockholdersEquity
198097000
CY2019Q3 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
196290000
CY2019Q3 us-gaap Stockholders Equity
StockholdersEquity
198097000
CY2018Q3 us-gaap Standard Product Warranty Accrual Current
StandardProductWarrantyAccrualCurrent
1093000
CY2019Q3 us-gaap Standard Product Warranty Accrual Current
StandardProductWarrantyAccrualCurrent
1216000
CY2018Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
463116000
CY2019Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
100162000
CY2018Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
95630000
CY2019Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
13019000
us-gaap Amortization Of Financing Costs And Discounts
AmortizationOfFinancingCostsAndDiscounts
5889000
us-gaap Amortization Of Financing Costs And Discounts
AmortizationOfFinancingCostsAndDiscounts
5494000
nvro Unrealized Gains And Losses On Foreign Currency Translation
UnrealizedGainsAndLossesOnForeignCurrencyTranslation
48000
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-5352000
us-gaap Increase Decrease In Other Noncurrent Liabilities
IncreaseDecreaseInOtherNoncurrentLiabilities
-2170000
us-gaap Increase Decrease In Other Noncurrent Liabilities
IncreaseDecreaseInOtherNoncurrentLiabilities
584000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-36750000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-10708000
nvro Unrealized Gains And Losses On Foreign Currency Translation
UnrealizedGainsAndLossesOnForeignCurrencyTranslation
-910000
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-9191000
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
5376000
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
-1194000
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
-3543000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-107000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
1360000
us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
558000
us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
1065000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-3866000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
1786000
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
6267000
CY2017Q4 us-gaap Stockholders Equity
StockholdersEquity
249172000
CY2018Q1 us-gaap New Accounting Pronouncement Or Change In Accounting Principle Effect Of Adoption Quantification
NewAccountingPronouncementOrChangeInAccountingPrincipleEffectOfAdoptionQuantification
967000
CY2018Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
1941000
CY2018Q1 us-gaap Adjustments Related To Tax Withholding For Share Based Compensation
AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation
215000
CY2018Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
8244000
CY2018Q1 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
226000
CY2018Q1 us-gaap Stockholders Equity
StockholdersEquity
242622000
CY2018Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
1465000
CY2018Q2 us-gaap Adjustments Related To Tax Withholding For Share Based Compensation
AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation
727000
CY2018Q2 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
3580000
CY2018Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
9314000
CY2018Q2 us-gaap Net Income Loss
NetIncomeLoss
-10620000
CY2018Q2 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
-45000
CY2018Q2 us-gaap Stockholders Equity
StockholdersEquity
245589000
CY2018Q3 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
494000
CY2018Q3 us-gaap Adjustments Related To Tax Withholding For Share Based Compensation
AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation
83000
CY2018Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
9453000
us-gaap Profit Loss
ProfitLoss
-89944000
us-gaap Profit Loss
ProfitLoss
-39598000
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
3306000
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
2845000
nvro Amortization Of Operating Lease Asset
AmortizationOfOperatingLeaseAsset
2423000
us-gaap Share Based Compensation
ShareBasedCompensation
31315000
us-gaap Share Based Compensation
ShareBasedCompensation
27018000
us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
1794000
us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
563000
us-gaap Provision For Doubtful Accounts
ProvisionForDoubtfulAccounts
106000
us-gaap Provision For Doubtful Accounts
ProvisionForDoubtfulAccounts
-444000
us-gaap Inventory Write Down
InventoryWriteDown
1832000
us-gaap Inventory Write Down
InventoryWriteDown
870000
us-gaap Payments To Acquire Available For Sale Securities Debt
PaymentsToAcquireAvailableForSaleSecuritiesDebt
178478000
us-gaap Payments To Acquire Available For Sale Securities Debt
PaymentsToAcquireAvailableForSaleSecuritiesDebt
137867000
us-gaap Proceeds From Sale And Maturity Of Available For Sale Securities
ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities
210703000
us-gaap Proceeds From Sale And Maturity Of Available For Sale Securities
ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities
128474000
nvro Investment In Private Company
InvestmentInPrivateCompany
5500000
CY2019Q3 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
22348000
CY2019Q3 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
3410000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
2041000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
7876000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
24684000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-17269000
us-gaap Payments Related To Tax Withholding For Share Based Compensation
PaymentsRelatedToTaxWithholdingForShareBasedCompensation
1057000
us-gaap Payments Related To Tax Withholding For Share Based Compensation
PaymentsRelatedToTaxWithholdingForShareBasedCompensation
1025000
us-gaap Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions
11761000
us-gaap Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions
7480000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
10704000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
6455000
us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
-216000
us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
-146000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-1578000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-21668000
CY2018Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
51872000
CY2017Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
43651000
CY2019Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
50294000
CY2018Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
21983000
us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
429000
us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
55000
CY2018 us-gaap Net Income Loss
NetIncomeLoss
-49200000
CY2018 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-5700000
us-gaap Net Income Loss
NetIncomeLoss
-89900000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-36800000
CY2019Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-396000000.0
CY2018Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-306100000
us-gaap Number Of Operating Segments
NumberOfOperatingSegments
1
CY2019Q3 us-gaap Foreign Currency Transaction Gain Loss Unrealized
ForeignCurrencyTransactionGainLossUnrealized
190000
CY2018Q3 us-gaap Foreign Currency Transaction Gain Loss Unrealized
ForeignCurrencyTransactionGainLossUnrealized
-6000
us-gaap Foreign Currency Transaction Gain Loss Unrealized
ForeignCurrencyTransactionGainLossUnrealized
690000
us-gaap Foreign Currency Transaction Gain Loss Unrealized
ForeignCurrencyTransactionGainLossUnrealized
-892000
CY2019Q2 us-gaap Standard Product Warranty Accrual Current
StandardProductWarrantyAccrualCurrent
1291000
CY2018Q2 us-gaap Standard Product Warranty Accrual Current
StandardProductWarrantyAccrualCurrent
943000
CY2018Q4 us-gaap Standard Product Warranty Accrual Current
StandardProductWarrantyAccrualCurrent
1236000
CY2019Q3 us-gaap Standard Product Warranty Accrual Warranties Issued
StandardProductWarrantyAccrualWarrantiesIssued
490000
CY2018Q3 us-gaap Standard Product Warranty Accrual Warranties Issued
StandardProductWarrantyAccrualWarrantiesIssued
597000
us-gaap Standard Product Warranty Accrual Warranties Issued
StandardProductWarrantyAccrualWarrantiesIssued
1426000
CY2019Q3 us-gaap Standard Product Warranty Accrual Payments
StandardProductWarrantyAccrualPayments
565000
CY2018Q3 us-gaap Standard Product Warranty Accrual Payments
StandardProductWarrantyAccrualPayments
447000
CY2019Q3 us-gaap Standard Product Warranty Accrual Current
StandardProductWarrantyAccrualCurrent
1216000
CY2019Q3 us-gaap Foreign Currency Transaction Gain Loss Realized
ForeignCurrencyTransactionGainLossRealized
-459000
us-gaap Foreign Currency Transaction Gain Loss Realized
ForeignCurrencyTransactionGainLossRealized
217000
CY2018Q4 us-gaap Cash Uninsured Amount
CashUninsuredAmount
4100000
CY2019Q3 us-gaap Money Market Funds At Carrying Value
MoneyMarketFundsAtCarryingValue
17300000
CY2018Q3 us-gaap Foreign Currency Transaction Gain Loss Realized
ForeignCurrencyTransactionGainLossRealized
-75000
CY2019Q3 nvro Inventory Write Down Cash And Non Cash
InventoryWriteDownCashAndNonCash
400000
us-gaap Foreign Currency Transaction Gain Loss Realized
ForeignCurrencyTransactionGainLossRealized
-1086000
us-gaap Use Of Estimates
UseOfEstimates
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Use of Estimates</p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The preparation of financial statements in accordance with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported in the condensed consolidated financial statements and accompanying notes. Significant accounting estimates and management judgments reflected in the condensed consolidated financial statements include items such as allowances for doubtful accounts; warranty obligations; clinical accruals; stock-based compensation; depreciation and amortization periods; inventory valuation; valuation of investments; and accounting for income taxes. Estimates are based on historical experience, where applicable, and other assumptions believed to be reasonable by the management. Actual results may differ from those estimates under different assumptions or conditions.</p>
us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Concentration of Credit Risk and Other Risks and Uncertainties</p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Financial instruments that potentially subject the Company to a concentration of credit risk consist of cash, cash equivalents and investments. The majority of the Company’s cash is held by one financial institution in the United States and is in excess of federally insured limits. The Company maintained investments in money market funds that were not federally insured during the periods ended September 30, 2019 and December 31, 2018.  The Company also held cash in foreign banks of approximately $8.9 million at September 30, 2019 and $4.1 million at December 31, 2018 that was not federally insured. The Company has not experienced any losses on its deposits of cash and cash equivalents.</p> <p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company’s convertible note hedge transactions, entered into in connection with the 2021 Notes, subject the Company to credit risk such that the counterparties may be unable to fulfill the terms of the transactions.  The associated risk is mitigated by limiting the counterparties to major financial institutions.</p> <p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In the international markets in which the Company participates, the Company uses </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">a combination of </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">a </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">direct sales force</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">, sales agents</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> and</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> independent</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> distributors to sell its products, while in the United States the Company utilizes a direct sales force. The Company performs ongoing credit evaluations of its direct customers and distributors, does not require collateral, and maintains allowances for potential credit losses on customer accounts when deemed necessary.</span></p> <p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">During the three and nine months ended September 30, 2019 and 2018, no single customer accounted for <span>10%</span> or more of the Company’s revenue. As of September 30, 2019 and December 31, 2018, no single customer accounted for <span>10%</span> or more of the accounts receivable balance.</p> <p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company is subject to risks common to medical device companies, including, but not limited to, new technological innovations, dependence on key personnel, protection of proprietary technology, compliance with government regulations, product liability, manufacturing quality and scaling, continued reimbursement from third-party payors,<span style="color:#1F497D;"> </span>uncertainty of market acceptance of products and the need to obtain additional financing. The Company is dependent on third-party manufacturers and suppliers, which, in some cases, are sole- or single-source suppliers.</p> <p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">There can be no assurance that the Company’s products or services will continue to be accepted in its existing marketplaces, nor can there be any assurance that any future products or services can be developed or manufactured at an acceptable cost and with appropriate performance characteristics, or that such products or services will be successfully marketed, if at all.</p> <p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company may choose to raise additional funds to further enhance its research and development efforts, for product expansion opportunities or to acquire a new business or products that are complementary to its business. There can be no assurance that such financing will be available or will be at terms acceptable by the Company.</p>
CY2019Q3 us-gaap Cash Uninsured Amount
CashUninsuredAmount
8900000
CY2018Q4 us-gaap Money Market Funds At Carrying Value
MoneyMarketFundsAtCarryingValue
15600000
CY2018Q3 nvro Inventory Write Down Cash And Non Cash
InventoryWriteDownCashAndNonCash
500000
nvro Inventory Write Down Cash And Non Cash
InventoryWriteDownCashAndNonCash
4500000
nvro Inventory Write Down Cash And Non Cash
InventoryWriteDownCashAndNonCash
900000
nvro Excess Inventory Charges
ExcessInventoryCharges
3600000
us-gaap Standard Product Warranty Description
StandardProductWarrantyDescription
limited one- to five-year warranty
us-gaap Asset Impairment Charges
AssetImpairmentCharges
0
CY2018Q3 us-gaap Income Tax Examination Penalties And Interest Expense
IncomeTaxExaminationPenaltiesAndInterestExpense
0
us-gaap Income Tax Examination Penalties And Interest Expense
IncomeTaxExaminationPenaltiesAndInterestExpense
0
CY2018Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
119000
CY2018Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
2825000
CY2019Q3 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
1213000
CY2019Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
4924000
CY2019Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
5073000
CY2019Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
5258000
CY2019Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Five
LesseeOperatingLeaseLiabilityPaymentsDueYearFive
5522000
CY2019Q3 us-gaap Lessee Operating Lease Liability Payments Due After Year Five
LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive
8086000
CY2019Q3 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
30076000
CY2019Q3 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
5342000
CY2019Q3 us-gaap Operating Lease Liability
OperatingLeaseLiability
24734000
CY2019Q3 us-gaap Operating Lease Cost
OperatingLeaseCost
1239000
CY2019Q3 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
21324000
CY2019Q3 us-gaap Operating Lease Liability
OperatingLeaseLiability
24734000
CY2019Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
11721000
CY2018Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
12801000
CY2019Q3 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
1112000
CY2018Q3 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
1078000
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
3306000
CY2019Q3 us-gaap Operating Lease Payments
OperatingLeasePayments
1010000
us-gaap Operating Lease Payments
OperatingLeasePayments
2809000
CY2019Q3 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
196290000
CY2019Q3 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
374000
CY2019Q3 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
196664000
CY2018Q4 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
231344000
CY2018Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
210000
CY2018Q4 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
231134000
CY2019Q3 us-gaap Available For Sale Securities Debt Maturities Within One Year Amortized Cost
AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost
163797000
CY2019Q3 us-gaap Available For Sale Securities Debt Maturities Within One Year Fair Value
AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue
164135000
CY2019Q3 us-gaap Available For Sale Securities Debt Maturities After One Through Five Years Amortized Cost
AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost
32493000
CY2019Q3 us-gaap Available For Sale Securities Debt Maturities After One Through Five Years Fair Value
AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue
32529000
CY2019Q3 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
196664000
CY2019Q3 us-gaap Inventory Raw Materials Net Of Reserves
InventoryRawMaterialsNetOfReserves
32442000
CY2018Q4 us-gaap Inventory Raw Materials Net Of Reserves
InventoryRawMaterialsNetOfReserves
37453000
CY2019Q3 us-gaap Inventory Finished Goods Net Of Reserves
InventoryFinishedGoodsNetOfReserves
58288000
CY2018Q4 us-gaap Inventory Finished Goods Net Of Reserves
InventoryFinishedGoodsNetOfReserves
54582000
CY2019Q3 us-gaap Inventory Net
InventoryNet
90730000
CY2018Q4 us-gaap Inventory Net
InventoryNet
92035000
CY2019Q3 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
23783000
CY2018Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
21557000
CY2019Q3 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
12062000
CY2018Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
8756000
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
2845000
CY2019Q3 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
28521000
CY2018Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
26792000
CY2019Q3 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
1677000
CY2018Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
1595000
CY2019Q3 us-gaap Accrued Income Taxes Current
AccruedIncomeTaxesCurrent
2257000
CY2018Q4 us-gaap Accrued Income Taxes Current
AccruedIncomeTaxesCurrent
2506000
CY2019Q3 nvro Accrued Clinical And Research Expenses Current
AccruedClinicalAndResearchExpensesCurrent
1958000
CY2018Q4 nvro Accrued Clinical And Research Expenses Current
AccruedClinicalAndResearchExpensesCurrent
1105000
CY2019Q3 us-gaap Interest Payable Current
InterestPayableCurrent
998000
CY2018Q4 us-gaap Interest Payable Current
InterestPayableCurrent
243000
CY2019Q3 us-gaap Standard Product Warranty Accrual Current
StandardProductWarrantyAccrualCurrent
1216000
CY2018Q4 us-gaap Standard Product Warranty Accrual Current
StandardProductWarrantyAccrualCurrent
1236000
CY2019Q3 nvro Inventory Related Liabilities
InventoryRelatedLiabilities
1732000
CY2018Q4 nvro Inventory Related Liabilities
InventoryRelatedLiabilities
790000
CY2019Q3 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
6689000
CY2018Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
4523000
CY2019Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
45048000
CY2018Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
38790000
us-gaap Standard Product Warranty Description
StandardProductWarrantyDescription
limited one- to five-year warranty
CY2017Q4 us-gaap Standard Product Warranty Accrual Current
StandardProductWarrantyAccrualCurrent
708000
us-gaap Standard Product Warranty Accrual Warranties Issued
StandardProductWarrantyAccrualWarrantiesIssued
1681000
us-gaap Standard Product Warranty Accrual Payments
StandardProductWarrantyAccrualPayments
1446000
us-gaap Standard Product Warranty Accrual Payments
StandardProductWarrantyAccrualPayments
1296000
CY2018Q3 us-gaap Standard Product Warranty Accrual Current
StandardProductWarrantyAccrualCurrent
1093000
nvro Expectation Period For First Obligation
ExpectationPeriodForFirstObligation
P12M
CY2019Q3 nvro Secured Convertible Note Receivable Measured At Amortized Cost
SecuredConvertibleNoteReceivableMeasuredAtAmortizedCost
5700000
CY2019Q3 nvro Value Of Certain Rights Measured At Cost
ValueOfCertainRightsMeasuredAtCost
1000000.0
CY2019Q3 us-gaap Loss Contingency Accrual At Carrying Value
LossContingencyAccrualAtCarryingValue
0
CY2018Q4 us-gaap Loss Contingency Accrual At Carrying Value
LossContingencyAccrualAtCarryingValue
0
CY2019Q3 us-gaap Net Income Loss
NetIncomeLoss
-17847000
CY2018Q3 us-gaap Net Income Loss
NetIncomeLoss
-11265000
us-gaap Net Income Loss
NetIncomeLoss
-89944000
us-gaap Net Income Loss
NetIncomeLoss
-39598000
CY2019Q3 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
30929938
CY2018Q3 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
30123188
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
30659117
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
29997201
CY2019Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.58
CY2018Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.37
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-2.93
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-1.32
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
7090135
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
6871021
CY2019Q3 us-gaap Defined Contribution Plan Employer Discretionary Contribution Amount
DefinedContributionPlanEmployerDiscretionaryContributionAmount
300000
us-gaap Defined Contribution Plan Employer Discretionary Contribution Amount
DefinedContributionPlanEmployerDiscretionaryContributionAmount
2900000
CY2018Q3 us-gaap Defined Contribution Plan Employer Discretionary Contribution Amount
DefinedContributionPlanEmployerDiscretionaryContributionAmount
300000
us-gaap Defined Contribution Plan Employer Discretionary Contribution Amount
DefinedContributionPlanEmployerDiscretionaryContributionAmount
2400000

Files In Submission

Name View Source Status
0001564590-19-041110-index-headers.html Edgar Link pending
0001564590-19-041110-index.html Edgar Link pending
0001564590-19-041110.txt Edgar Link pending
0001564590-19-041110-xbrl.zip Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
nvro-10q_20190930.htm Edgar Link pending
nvro-10q_20190930_htm.xml Edgar Link completed
nvro-20190930.xsd Edgar Link pending
nvro-20190930_cal.xml Edgar Link unprocessable
nvro-20190930_def.xml Edgar Link unprocessable
nvro-20190930_lab.xml Edgar Link unprocessable
nvro-20190930_pre.xml Edgar Link unprocessable
nvro-ex101_16.htm Edgar Link pending
nvro-ex102_14.htm Edgar Link pending
nvro-ex103_17.htm Edgar Link pending
nvro-ex311_7.htm Edgar Link pending
nvro-ex312_9.htm Edgar Link pending
nvro-ex321_6.htm Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending